Simvastatin inducing PC3 prostate cancer cell necrosis mediated by calcineurin and mitochondrial dysfunction

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Simvastatin is a widely used statin medication.
• Prostate cancer cells (PC3) are a common model for studying cancer drug toxicity.
• Understanding simvastatin's cellular mechanisms is crucial for its therapeutic application and toxicity management.

Purpose of the Study:

• To elucidate the distinct mechanisms underlying simvastatin-induced apoptosis and necrosis in PC3 human prostate cancer cells.
• To investigate the roles of mevalonic acid, calcineurin, and mitochondrial pathways in simvastatin toxicity.

Main Methods:

• PC3 cells were treated with varying concentrations of simvastatin (10 microM and 60 microM).
• Apoptosis and necrosis were assessed.
• Key cellular parameters including cytosolic free Ca(2+) concentration, respiration rate, and mitochondrial membrane potential were measured.
• The effects of mevalonic acid, cyclosporin A, FK506, and bongkrekic acid were evaluated.

Main Results:

• Low-dose simvastatin (10 microM) induced apoptosis, preventable by mevalonic acid, indicating dependence on 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibition.
• High-dose simvastatin (60 microM) induced necrosis, characterized by increased cytosolic Ca(2+), decreased respiration, and reduced mitochondrial potential.
• Necrosis and mitochondrial dysfunction were sensitive to calcineurin inhibitors (cyclosporin A, FK506) and bongkrekic acid, suggesting a role for calcineurin and mitochondrial permeability transition (MPT).

Conclusions:

• Simvastatin-induced apoptosis in PC3 cells is primarily mediated by HMG-CoA reductase inhibition and is independent of MPT.
• Simvastatin-induced necrosis involves calcineurin-dependent mitochondrial dysfunction.
• These findings differentiate the pathways of simvastatin toxicity, offering insights into targeted therapeutic strategies and side effect mitigation.